# Insmed Gene Therapy LLC: Phase 1 study closed enrollment, 12 enrolled (Duchenne Muscular Dystrophy)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Insmed Gene Therapy LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD) |
| NCT ID | NCT06817382 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Duchenne Muscular Dystrophy |
| Intervention types | genetic |
| Target enrollment | 12 |
| Site countries | United States |
| Posted | 2025-02-10 |
| Planned start | 2025-07-22 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-28 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06817382). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.